Literature DB >> 33447304

Cirrhosis Is Associated With Worse Outcomes in Ischemic Colitis: A Nationwide Retrospective Study.

Eric Then1, Caitlin Lund2, Dustin J Uhlenhopp3, Tagore Sunkara4, Vinaya Gaduputi4.   

Abstract

BACKGROUND: Ischemic colitis (IC) occurs when the blood supply of the large intestine becomes compromised. Cirrhosis is a disease entity in which there is a delicate balance between pro-coagulant and anti-coagulant states. Our aim was to examine the impact cirrhosis has on outcomes in patients with ischemic colitis.
METHODS: A retrospective analysis of patients hospitalized with IC in 2017 was evaluated using the National Inpatient Sample database. Baseline demographic data, length of hospital stay (LOS), total hospital charge, rates of colectomy and in-hospital mortality were extracted from the database. Categorical variables were compared using the Chi-square test and continuous variables were compared using t-test.
RESULTS: A total of 29,035 patients with IC were identified, while 420 of these patients also had cirrhosis. Patients with IC and cirrhosis were noted to be younger age at presentation when compared to patients with IC and no cirrhosis (mean 63.9 years vs. 70.4 years; P < 0.001). When comparing both groups, IC patients with cirrhosis were more likely to be male (50% vs. 26.1%; P < 0.001), Black (10.9% vs. 7.6%; P = 0.013) and Hispanic (18% vs. 6.1%; P < 0.001). We found that IC patients with cirrhosis had a longer LOS (7.3 days vs. 4.8 days; P < 0.001), higher total hospital charge ($84,769 vs. $48,347; P < 0.001) and higher mortality rate (10.7% vs. 3.6%; P < 0.001); however, the presence of cirrhosis was not associated with increased odds of undergoing colectomy (odds ratio: 0.31; 95% confidence interval: 0.07 - 1.27; P = 0.104).
CONCLUSIONS: The presence of cirrhosis is associated with increased odds of in-hospital mortality in those presenting with IC. This compounds the already high rates of mortality in patients that undergo surgery for IC and could reflect lack of reserve to withstand the ischemic episode in the setting of cirrhosis. Though odds of undergoing colectomy is not increased, patients with cirrhosis warrant closer observation. Copyright 2020, Then et al.

Entities:  

Keywords:  Cirrhosis; Colectomy; Ischemic colitis; Mortality; National Inpatient Sample

Year:  2020        PMID: 33447304      PMCID: PMC7781274          DOI: 10.14740/gr1339

Source DB:  PubMed          Journal:  Gastroenterology Res        ISSN: 1918-2805


Introduction

Ischemic colitis (IC) is a gastrointestinal (GI) disorder that occurs when the blood supply of the large intestine becomes compromised and is often categorized in occlusive versus non-occlusive causes. Cirrhosis is a disease entity in which there is a delicate balance between pro-coagulant and anti-coagulant states. If altered, this may result in excessive bleeding or clot formation. It is known that portal hypertension leads to associated colopathies, most notably colonic vascular ectasias and rectal varices [1]. Dilated and congested capillaries, and capillaries with irregularly thickened walls are seen in higher numbers in patients with portal hypertension [2]. It has been noted that colonic wall changes can be seen on computed tomography (CT) scans in higher rates in patients with cirrhosis, with up to 37% having colonic wall thickening notable on CT [2]. Classic IC usually affects the left side of the colon most commonly in “watershed areas” such as hepatic flexure and sigmoid colon [3]. The normal colonic response to ischemia is vasodilation; however, in patients with portal hypertension, there is little reserve to meet the demand of ischemia. Cirrhosis and associated portal venous hypertension result in microvascular colopathies, which can lead to venous congestion and may make the colon more susceptible to ischemic insults [4]. While colopathies associated with portal hypertension are more commonly seen in the right hemi-colon, it can be assumed that the colon would be more susceptible to ischemic insult due to the lack of compensatory mechanisms [4]. Although uncommon, lower GI bleeding in cirrhotic patients is associated with a high mortality rate of 17% [5]. Ischemic bowel disease accounts for 3-9% of all cases of LGIB and increases with advancing age. This would be expected to be higher in patients with cirrhosis or predisposing factors for ischemia [5]. Our study aimed to examine the impact cirrhosis has on the severity of IC. The specific study objectives were to characterize if there was a significant difference in hospital length of stay (LOS) between patients with IC alone as compared to those with IC and cirrhosis. We also evaluated if there was a difference in rate of in-hospital colectomy for the two groups.

Materials and Methods

Data source

This was a retrospective cohort study of patients admitted to acute care hospitals in the United States of America (US) with IC in the year 2017. Patients were extracted from the Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS) database. The NIS is the largest publicly available inpatient database in the USA and is sponsored by the Agency for Healthcare Research Quality (AHRQ). The 2017 NIS sampling frame includes data from 46 states, covering more than 97% of the total US population [6]. A 20% probability sample was collected and subsequently weighted to ensure that the selected population was nationally representative. Each admission in the database was assigned one principal diagnosis, up to 39 secondary diagnoses, and up to 25 procedures. These variables are defined via International Classification of Disease, 10th revision, and Clinical Modification (ICD-10-CM) codes.

Study population

Patients with the principal ICD-10-CM diagnosis of IC were included in our study. After extracting these patients, they were then divided into two groups. The first group consisted of patients with IC as the principal diagnosis who did not have cirrhosis listed as a secondary diagnosis. The second group consisted of patients with IC as the principal diagnosis while concurrently having the secondary diagnosis of cirrhosis from any cause.

Study variables

We extracted baseline patient and hospital characteristics for each admission that met our inclusion criteria. Patient characteristics included age (years), gender, race (White, Black, Hispanic, Asian or Pacific Islander, Native American), insurance type and Charlson comorbidity index. Hospital characteristics included hospital region and hospital bed size. Additionally, we extracted the total number of colectomies (via ICD-10-CM procedure codes) that were performed for each individual admission across all study groups. Other variables that were extracted included total number of deaths, LOS and total hospital charge. Total hospital charge refers to the amount of money each hospital billed the payer for the service provided during each admission.

Outcomes

Our primary endpoint was to elucidate if there was a statistically significant difference in LOS between patients with IC alone compared to those with IC and cirrhosis. Secondary endpoints included comparing the proportions of colectomies performed, total hospital charges and total deaths between the two groups.

Statistical analysis

Statistical analysis was conducted using STATA software, version 15.0 (StataCorp., College Station, Texas, USA). NIS provides discharge level weights that facilitate estimating the total number of patients with IC across the USA. Descriptive statistics were used to describe the characteristics of the cohorts of patients with IC alone, and those with IC and cirrhosis. Fisher’s exact test was used to compare proportions, and Welch’s t-test was used to compare means between the cohorts. Multivariant logistic regression analyses were conducted to evaluate factors that were associated with in-hospital colectomy and in-hospital mortality. Variables with a P-value ≤ 0.1 on univariant analysis were entered and further computed on the multivariate logistic regression model. Associations between the study and outcome variables were described using odds ratio (OR) at 95% confidence interval (CI). A two-tailed P-value < 0.05 was considered statistically significant. All procedures performed in studies involving human participants were in accordance with the ethical standards of institutional and/or research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Institutional Review Board approval is not required for this study.

Results

Patient and hospital characteristics

Figure 1 shows a flow diagram for the patients included in our study. A total of 29,035 patients with IC were identified. Of those, a total of 28,615 patients had IC with no cirrhosis, and 420 patients had IC with concurrent cirrhosis. Patients with IC and cirrhosis were found to have a statistically significant younger age of presentation when compared to patients with IC and no cirrhosis (mean 63.9 years vs. 70.4 years; P < 0.001). When compared to patients without cirrhosis, IC patients with cirrhosis were more likely to be male (50% vs. 26.1%; P < 0.001), Black (10.9% vs. 7.6%; P < 0.013) and Hispanic (18% vs. 6.1%; P < 0.001). It is important to note however, most patients were predominately White in both groups (Table 1). Similarly, there were statistically significant differences in hospital region, hospital bed size and insurance between the two groups (Table 1).
Figure 1

Flow diagram of patient selection.

Table 1

Baseline Demographic Characteristics

IC + cirrhosis (N = 420)IC with no cirrhosis (N = 28,615)P value
Age (years)63.970.40.0001
Gender
  Male210 (50%)7,469 (26.1%)-
  Female210 (50%)21,146 (73.9%)0.0001
Race
  White283 (67.5%)23,436 (81.9%)0.0001
  Black46 (10.9%)2,175 (7.6%)0.013
  Hispanic76 (18%)1,745 (6.1%)0.0001
  Asian/PI0 (0%)687 (2.4%)0.002
  Native American5 (1.2%)86 (0.3%)0.005
  Other10 (2.4%)486 (1.7%)0.3778
Hospital region
  Northeast60 (14.2%)6,066 (21.2%)0.0007
  Midwest130 (31%)7,383 (25.8%)0.0194
  South155 (37%)9,987 (34.9%)0.4217
  West75 (17.8%)5,179 (18.1%)0.949
Hospital bed size
  Small50 (11.9%)6,066 (21.2%)0.0001
  Medium160 (38.1%)9,157 (32%)0.0092
  Large210 (50%)13,392 (46.8%)0.2094
Insurance
  Medicare205 (48.8%)20,317 (71%)0.0001
  Medicaid95 (22.6%)1,774 (6.2%)0.0001
  Private insurance95 (22.6%)5,580 (19.5%)0.124
  Self-pay10 (2.4%)458 (1.6%)0.2866
  No charge0 (0%)28 (0.1%)0.5213
  Other15 (3.6%)458 (1.6%)0.0029

IC: ischemic colitis; PI: Pacific Islander.

Flow diagram of patient selection. IC: ischemic colitis; PI: Pacific Islander.

In-hospital colectomy rates

When comparing rates of in-hospital colectomies, patients with IC and cirrhosis had a statistically significant decreased rate of colectomy when compared with patients with IC without the secondary diagnosis of cirrhosis (2.3% vs. 5.1%; P = 0.015) (Table 2). However, these findings were not reflected on multivariate analysis (Table 3). When adjusting for age, gender, race and co-morbid conditions (atrial fibrillation, coronary artery disease, congestive heart failure, peripheral vascular disease, end-stage renal disease, hypertension and diabetes mellitus), the presence of cirrhosis was not associated with a statistically significant difference in odds of undergoing colectomy (OR: 0.31; 95% CI: 0.07 - 1.27; P = 0.104). Atrial fibrillation was associated with statistically significant increased odds of in-hospital colectomy (OR: 1.95; 95% CI: 1.42 - 2.64; P < 0.001). Patients who were Black or Hispanic were also at increased odds of colectomy (OR: 1.68; 95% CI: 1.11 - 2.53; P = 0.013 and OR: 6.24; 95% CI: 1.83 - 21.30; P = 0.003, respectively).
Table 2

Hospital Outcomes

IC + cirrhosis (N = 420)IC with no cirrhosis (N = 28,615)P value
LOS (days)7.34.80.0001
Total charge (USD)$84,769$48,3470.0002
Died45 (10.7%)1,045 (3.6%)0.0001
Colectomy10 (2.3%)1,465 (5.1%)0.0153

IC: ischemic colitis; LOS: length of hospital stay; USD: United States Dollar; IC: ischemic colitis.

Table 3

Multivariate Analysis for In-Hospital Colectomy

Odds ratio95% CIP value
Cirrhosis0.310.07 - 1.270.104
A-fib1.951.43 - 2.640.000
CAD1.050.77 - 1.420.738
CHF1.220.82 - 1.820.305
PVD1.110.71 - 1.730.633
ESRD1.500.93 - 2.420.095
HTN0.840.63 - 1.110.224
DM1.120.84 - 1.490.423
Age0.980.97 - 0.990.005
Gender
  Male (reference)---
  Female0.560.43 - 0.720.000
Race
  White (reference)---
  Black1.681.11 - 2.530.013
  Hispanic1.090.66 - 1.780.726
  Asian/PI1.130.51 - 2.490.758
  Native American6.241.83 - 21.300.003
  Other1.210.50 - 2.930.667

A-fib: atrial fibrillation; CAD: coronary artery disease; CHF: congestive heart failure; CI: confidence interval; DM: diabetes mellitus; ESRD: end-stage renal disease; HTN: hypertension; PVD: peripheral vascular disease; PI: Pacific Islander.

IC: ischemic colitis; LOS: length of hospital stay; USD: United States Dollar; IC: ischemic colitis. A-fib: atrial fibrillation; CAD: coronary artery disease; CHF: congestive heart failure; CI: confidence interval; DM: diabetes mellitus; ESRD: end-stage renal disease; HTN: hypertension; PVD: peripheral vascular disease; PI: Pacific Islander.

Resource utilization and mortality

The mean LOS, total hospital charges and total deaths for both groups are presented in Table 2. Patients with IC and cirrhosis had statistically significant higher total hospital charge ($84,769 vs. $48,347; P < 0.001) and longer LOS (7.3 days vs. 4.8 days; P < 0.001). Regarding in-hospital mortality rates, patients with IC and cirrhosis had a statistically significant increased mortality rate when compared to patients without cirrhosis (10.7% vs. 3.6%; P < 0.001). These findings were sustained on multivariate analysis (Table 4). When adjusting for age, gender, race and co-morbid conditions (atrial fibrillation, coronary artery disease, congestive heart failure, peripheral vascular disease, end-stage renal disease, hypertension and diabetes mellitus), the presence of cirrhosis was associated with statistically significant increased odds of in-hospital mortality (OR: 3.15; 95% CI: 1.46 - 6.79; P = 0.003). Multivariate analysis demonstrated that atrial fibrillation (OR: 2.31; 95% CI: 1.68 - 3.16; P < 0.001), peripheral vascular disease (OR: 1.69; 95% CI: 1.05 - 2.73; P = 0.030) and end-stage renal disease (OR: 3.29; 95% CI: 1.93 - 5.62; P < 0.001) increased odds of in hospital mortality.
Table 4

Multivariate Analysis for In-Hospital Mortality

Odds ratio95% CIP value
Cirrhosis3.151.46 - 6.790.003
A-fib2.311.68 - 3.160.000
CAD0.870.62 - 1.220.430
CHF1.300.88 - 1.920.187
PVD1.691.05 - 2.730.030
ESRD3.291.93 - 5.620.000
HTN0.590.42 - 0.830.002
DM0.750.53 - 1.050.096
Age1.031.02 - 1.05
Gender
  Male (reference)---
  Female0.720.53 - 0.990.046
Race
  White (reference)---
  Black1.300.75 - 2.240.347
  Hispanic1.140.64 - 2.040.643
  Asian/PI0.870.31 - 2.380.791
  Native American1.970.28 - 13.660.492
  Other2.050.85 - 4.950.109

A-fib: atrial fibrillation; CAD: coronary artery disease; CHF: congestive heart failure; CI: confidence interval; DM: diabetes mellitus; ESRD: end-stage renal disease; HTN: hypertension; PVD: peripheral vascular disease; PI: Pacific Islander.

A-fib: atrial fibrillation; CAD: coronary artery disease; CHF: congestive heart failure; CI: confidence interval; DM: diabetes mellitus; ESRD: end-stage renal disease; HTN: hypertension; PVD: peripheral vascular disease; PI: Pacific Islander.

Discussion

There are few studies to evaluate an association between classic IC and cirrhosis. Most of the literature and case studies of IC in the setting of cirrhosis surround phlebosclerotic colitis and right-sided colopathies [3]. Our study is significant in that the pathophysiology of cirrhosis may predispose the colon to ischemic insult and could bode as a marker for worse outcomes in patients with classic IC. Although there have been other studies examining prognostic factors in IC, such as the ischemic colitis mortality risk (ICMR) score [7-10], none have included cirrhosis or portal hypertension as a potential prognostic or risk factor. This is despite some studies that suggest higher serum albumin, which is deranged in cirrhosis, is associated with survival benefit [10]. Even when adjusted for age, gender, race and co-morbid conditions, our study showed patients with IC and cirrhosis had a statistically significant increased mortality rate when compared to patients without cirrhosis. Presence of cirrhosis is associated with a greater than three-fold increased odds of in-hospital mortality. This compounds the already high rates of mortality in patients that undergo surgery for IC, up to 54% in some studies, and could be a reflection of lack of reserve to withstand the ischemic episode in the setting of cirrhosis [11-16]. With increased mortality we would have expected in-hospital colectomy rates also to be higher in the IC with cirrhosis group; however, colectomy rates were actually lower, though this was not significant when adjusted for age, gender, race and co-morbidities. Understanding that cirrhosis increases overall perioperative mortality, Child-Pugh class and model for end-stage liver disease score were not used to categorize surgical risk or severity of cirrhosis, and therefore appropriateness of surgery was not evaluated in this study due to its retrospective nature. It is plausible that surgical risk assessment may have affected colectomy rates for IC in the setting of cirrhosis despite possibly worse severity with concurrent diseases, but this would need to be studied further, ideally in a prospectively designed study. Colectomy rates overall were low for both IC with cirrhosis, and IC without cirrhosis groups (2.3% and 5.1%, respectively), which is keeping with prior meta-analyses and reviews, as non-occlusive IC is predominantly managed medically in about 80% of cases [14-16]. It is important to note that occlusive or non-occlusive etiologies and severity of IC were not factored into this study. Patients with IC and cirrhosis had higher total hospital charges and longer LOS when compared to those without cirrhosis. This may reflect need for additional consultants and/or surgical or endoscopic intervention, if performed, in these complicated patients. Any procedure would be expected to increase cost as well as LOS. In examination of the populations affected, patients with both IC and cirrhosis were more likely to be younger at age of presentation compared to those without cirrhosis. Compared to patients without cirrhosis, patients with IC and cirrhosis were more likely to be male, black and Hispanic, although patients in both groups were predominantly White. In contrast, the population of cirrhosis in the USA trends toward male, non-Hispanic blacks and Mexican-Americans, and are of older age [17-19]; however, the population dynamics of cirrhosis continue to change over time, and are expected to continue to do so, as rates of NASH and alcohol-related cirrhosis continue to increase and rates of hepatitis C-related cirrhosis decline [20]. Our study was hindered by multiple limitations. The first limitation is the retrospective design, which carries inherit weaknesses. Our study is constrained to patients with acute IC severe enough to be hospitalized and, thus, does not assess the full spectrum of disease. With the usually benign and transient nature of most IC cases, self-limited, symptomatic outpatient cases would not have been captured by our methodology. Another limitation of our study is the nature of the NIS database itself. The NIS database only analyzes in-hospital mortality/cost/need for surgery for one admission, which can underestimate true mortality/cost/need for surgery. It is not possible to study prolonged periods, such as 30-, 60-, or 90-day mortalities. The database is limited to one principal diagnosis, and as such, may not capture patients with IC that were admitted for other more costly reasons. Additionally, we rely on ascertainment of IC using diagnostic codes, without methods to confirm the diagnosis by reviewing histology or colonoscopy reports, which can potentially lead to misclassification bias. Considering the wide variation seen in presentations of IC, many cases of IC may be misdiagnosed with other conditions such as infectious colitis, inflammatory bowel disease, pseudomembranous colitis, diverticulitis and colon carcinoma [21, 22]. Despite these limitations, our study is derived from a large, robust and generalizable sample size with data from multiple hospitals nationwide. Single-institution studies are not easily generalized, making it important to evaluate this disease on national data. The volume of patients included in our study relative to previous reports in the literature provides important information for patients and clinicians. This analysis provides additional clinical guidance in predicting those at increased risk for increased mortality due to IC and may help establish realistic expectations with patients and their families. In conclusion, we found that the presence of cirrhosis portends poorer outcomes in patients with IC. This was evidenced by an increased odds of in-hospital mortality and LOS but did not result in higher rates of in-hospital colectomy. Given these findings, patients with cirrhosis warrant closer observation. This is the first study that evaluated cost of this condition. We further advocate that any future research evaluate cost and also consider race as a prognostic indicator considering well-known healthcare disparities. This would allow us to better evaluate the societal impact of IC and cirrhosis and further aid in development of public health policy.
  21 in total

1.  Intussusception and colonic ischemia in portal hypertension: a case report.

Authors:  Timothy P Plackett; Lisa C Coviello; Christina M Belnap; Kimberley J Phillips; Ronald A Gagliano; Carrie A Sims
Journal:  Hawaii Med J       Date:  2010-02

2.  Prognostic factors for mesenteric infarction: multivariate analysis of 187 patients with regard to patient age.

Authors:  Joerg-Peter Ritz; Christoph-Thomas Germer; Heinz J Buhr
Journal:  Ann Vasc Surg       Date:  2005-05       Impact factor: 1.466

3.  The outcomes and prognostic factors of surgical treatment for ischemic colitis: what can we do for a better outcome?

Authors:  Seung-Bum Ryoo; Heung-Kwon Oh; Heon-Kyun Ha; Sang Hui Moon; Eun Kyung Choe; Kyu Joo Park
Journal:  Hepatogastroenterology       Date:  2014 Mar-Apr

4.  Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study.

Authors:  C Huerta; E Rivero; M A Montoro; L A García-Rodriguez
Journal:  Aliment Pharmacol Ther       Date:  2011-03-01       Impact factor: 8.171

5.  The Epidemiology of Cirrhosis in the United States: A Population-based Study.

Authors:  Steven Scaglione; Stephanie Kliethermes; Guichan Cao; David Shoham; Ramon Durazo; Amy Luke; Michael L Volk
Journal:  J Clin Gastroenterol       Date:  2015-09       Impact factor: 3.062

6.  Ischemic colitis: who will survive?

Authors:  Christoph Reissfelder; Hussein Sweiti; Dalibor Antolovic; Nuh N Rahbari; Stefan Hofer; Markus W Büchler; Jürgen Weitz; Moritz Koch
Journal:  Surgery       Date:  2011-01-17       Impact factor: 3.982

7.  Ischemic colitis: analysis of risk factors for postoperative mortality.

Authors:  Dalibor Antolovic; Moritz Koch; Ulf Hinz; Dominik Schöttler; Thomas Schmidt; Ulrike Heger; Jan Schmidt; Markus W Büchler; Jürgen Weitz
Journal:  Langenbecks Arch Surg       Date:  2008-02-20       Impact factor: 3.445

8.  Phlebosclerotic colitis in a cirrhotic patient with portal hypertension: the first case in Korea.

Authors:  Ha Yan Kang; Ran Noh; So Mi Kim; Hyun Deok Shin; Se Young Yun; Il Han Song
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

9.  Poor prognostic factors in patients who underwent surgery for acute non-occlusive ischemic colitis.

Authors:  Minsu Noh; Song Soo Yang; Seok Won Jung; Jae Ho Park; Yeong Cheol Im; Kyu Yeol Kim
Journal:  World J Emerg Surg       Date:  2015-03-08       Impact factor: 5.469

10.  The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-01-22
View more
  2 in total

1.  Congestive Heart Failure Is Associated With Worse Outcomes in Patients With Ischemic Colitis: A Nationwide Study.

Authors:  Ratib Mahfouz; Landon A Kozai; Adham E Obeidat; Mohammad Darweesh; Mahmoud M Mansour; Mustafa F Douglas; Eric Berthiaume
Journal:  Cureus       Date:  2022-04-20

2.  Lactulose-Induced Ischemic Colitis: A Rare Presentation and an Overview of Possible Etiologies of the Disease.

Authors:  Zaryab Umar; Usman Ilyas; Deesha Shah; Nso Nso; Allison Foster; Milana Zirkiyeva
Journal:  Cureus       Date:  2022-04-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.